Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy

Thrombosis Research

Volumn 114, Issue 2, 2004, Pages 83-89

  Jonsson, Magnus ^a   Hillarp, Andreas ^a   Svensson, Peter ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

INR; international normalized ratio; international sensitivity index; ISI; Oral anticoagulation; Point of care; Prothrombin time; prothrombin time; PT; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; CAPILLARY BLOOD; CORRELATION ANALYSIS; HEART ATRIUM FIBRILLATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTERNATIONALITY; POINT-OF-CARE SYSTEMS; PROTHROMBIN TIME; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 4043147794     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.04.010     Document Type: Article

References (13)

1. Hirsh J., Dalen J., Anderson D.R., Poller L., Bussey H., Ansell J., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119(1 Suppl.):2001;8S-21S
2. Själander A., Engström G., Berntorp E., Svensson P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J. Intern. Med. 254(5):2003;434-438
3. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 348:1996;423-428
4. WHO Technical Report Series Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. WHO Expert Committee on Biological Standardization. World Health Organization, Annex 3. 889:1999;64-93
5. Quick A. The prothrombin time in haemophilia and in obstructive jaundice. J. Biol. Chem. 109:1935;73-74
6. Price C.P. Point of care testing. BMJ. 322:2001;1285-1288
7. Vacas M., Lafuente P.J., Cuesta S., Iriarte J.A. Comparative study of a portable monitor for prothrombin time determination, CoaguChek, with three systems for control of oral anticoagulant treatment. Haemostasis. 28:1998;321-328
8. Gosselin R., Owings J.T., White R.H., Hutchinson R., Branch J., Mahackian K., et al. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods. Thromb. Haemost. 83:2000;698-703
9. Owren P.A., Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. Clin. Lab. Invest. 1951;201-208
10. Hillarp A., Egberg N., Nordin G., Stigendal L., Fagerberg I., Lindahl T.L. Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme. Thromb. Haemost. 91:2004;300-307
11. Walsh P.N. Roles of factor XI, platelets and tissue factor-initiated blood coagulation. J. Thromb. Haemost. 1:2003;2081-2086
12. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism following anticoagulant therapy. Am. J. Med. 104:1998;332-338
13. van den Besselaar A.M., Meeuwisse-Braun J., van Schaefer-Mansfeld H., van Rijn C., Witteveen E. A comparison between capillary and venous blood international normalized ratio determinations in a portable prothrombin time device. Blood Coagul. Fibrinolysis. 11:2000;559-562